Regeneron Pharmaceuticals, Inc. (REGN) income statement
NASDAQ · Healthcare · Biotechnology · 15,410 employees · CEO Leonard S. Schleifer
- Price
- $927.89 +13.33%
- Market cap
- $95.5B
- Enterprise value
- $94.6B
- Last report
- Q3 '26 filed 2026-10-30
- Next report
- 2027-01-28 EPS est. $24.25
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $5.12B for Q3 '26 (+36.3% year on year), operating income of $2.05B (40.0% of revenue) and net income of $1.95B. Over the last four quarters revenue was $16.9B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.43B | $3.15B | $3.55B | $3.72B | $3.79B | $3.03B | $3.68B | $3.75B | $3.88B | $3.61B | $4.29B | $5.12B | |
| Cost of revenue | $629M | $434M | $480M | $491M | $565M | $464M | $530M | $522M | $585M | $669M | $577M | $574M | |
| Gross profit | $2.81B | $2.71B | $3.07B | $3.23B | $3.22B | $2.56B | $3.15B | $3.23B | $3.3B | $2.94B | $3.71B | $4.54B | |
| Research & development | $1.05B | $1.26B | $1.22B | $1.33B | $1.43B | $1.34B | $1.43B | $1.56B | $1.63B | $1.65B | $1.63B | $1.82B | |
| General & administrative | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $678M | |
| Other operating expenses | -$500K | $15.3M | $14.6M | $8M | $15.5M | $0 | $0 | -$10M | $18.7M | $0 | $0 | $0 | |
| Operating expenses | $1.75B | $1.96B | $2B | $2.05B | $2.23B | $1.97B | $2.07B | $2.21B | $2.42B | $2.29B | $2.29B | $2.49B | |
| Operating income | $1.05B | $751M | $1.07B | $1.18B | $990M | $592M | $1.08B | $1.03B | $880M | $643M | $1.42B | $2.05B | |
| Interest income | $149M | $162M | $179M | $187M | $183M | $174M | $175M | $175M | $193M | $184M | $183M | $182M | |
| Interest expense | $18.3M | $16.1M | $14.8M | $13.8M | $10.5M | $8.7M | $3.6M | $19.3M | $12.2M | $12.9M | $11M | $10.6M | |
| Other non-operating income (gains on investments, FX ...) | -$115M | $34.6M | -$573M | -$327M | $21.6M | -$322M | -$443M | -$756M | -$176M | -$201M | -$118M | -$247M | |
| Total non-operating income | $96.9M | -$50.7M | $559M | $314M | -$32.1M | $313M | $439M | $737M | $164M | $188M | $107M | $236M | |
| Income before tax | $1.15B | $701M | $1.63B | $1.49B | $958M | $905M | $1.52B | $1.76B | $1.04B | $831M | $1.53B | $2.28B | |
| Income tax | -$12M | -$21.3M | $196M | $152M | $40.4M | $96.3M | $127M | $303M | $199M | $104M | $231M | $335M | |
| Net income | $1.16B | $722M | $1.43B | $1.34B | $918M | $809M | $1.39B | $1.46B | $845M | $727M | $1.3B | $1.95B | |
| EPS (basic) | $10.88 | $6.70 | $13.25 | $12.40 | $8.53 | $7.58 | $13.24 | $14.09 | $8.21 | $6.99 | $12.59 | $19.16 | |
| EPS (diluted) | $10.19 | $6.27 | $12.41 | $11.54 | $8.06 | $7.27 | $12.81 | $13.62 | $7.86 | $6.75 | $12.20 | $18.45 | |
| Shares (basic, weighted) | 107M | 108M | 108M | 108M | 108M | 107M | 105M | 104M | 103M | 104M | 103M | 102M | |
| Shares (diluted, weighted) | 114M | 115M | 115M | 116M | 114M | 111M | 109M | 107M | 108M | 108M | 107M | 106M | |
| Depreciation & amortization | $113M | $114M | $121M | $122M | $126M | $127M | $135M | $137M | $145M | $123M | $124M | $121M | |
| EBITDA | $1.28B | $831M | $1.76B | $1.63B | $1.1B | $1.04B | $1.66B | $1.92B | $1.2B | $967M | $1.66B | $2.42B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.86B | $5.87B | $6.71B | $6.56B | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B | |
| Cost of revenue | $404M | $543M | $582M | $975M | $1.36B | $2.72B | $1.71B | $2.24B | $1.97B | $2.1B | |
| Gross profit | $4.46B | $5.33B | $6.13B | $5.58B | $7.14B | $13.3B | $10.5B | $10.9B | $12.2B | $12.2B | |
| Research & development | $1.95B | $1.93B | $2.04B | $2.24B | $2.5B | $2.62B | $3.06B | $3.99B | $5.23B | $5.85B | |
| Other operating expenses | $0 | $0 | $0 | -$209M | -$280M | -$45.6M | -$89.9M | -$2.1M | $53.4M | $114M | |
| Operating expenses | $3.13B | $3.25B | $3.59B | $3.37B | $3.56B | $4.4B | $5.08B | $6.52B | $8.24B | $8.66B | |
| Operating income | $1.33B | $2.08B | $2.53B | $2.21B | $3.58B | $8.95B | $5.39B | $4.35B | $3.99B | $3.58B | |
| Interest income | $0 | $0 | $0 | $0 | $0 | $0 | $160M | $496M | $711M | $717M | |
| Interest expense | $7.2M | $25.1M | $28.2M | $30.2M | $56.9M | $57.3M | $59.4M | $73M | $55.2M | $43.8M | |
| Other non-operating income (gains on investments, FX ...) | -$6.27M | -$24M | -$47.3M | -$249M | -$291M | -$436M | $467M | $76.3M | -$844M | -$1.7B | |
| Total non-operating income | -$926K | -$1.08M | $19.1M | $219M | $234M | $379M | -$527M | -$149M | $789M | $1.65B | |
| Income before tax | $1.33B | $2.08B | $2.55B | $2.43B | $3.81B | $9.33B | $4.86B | $4.2B | $4.78B | $5.23B | |
| Income tax | $434M | $880M | $109M | $313M | $297M | $1.25B | $520M | $246M | $367M | $726M | |
| Net income | $896M | $1.2B | $2.44B | $2.12B | $3.51B | $8.08B | $4.34B | $3.95B | $4.41B | $4.5B | |
| EPS (basic) | $8.55 | $11.27 | $21.29 | $19.38 | $32.65 | $76.40 | $40.51 | $37.05 | $40.90 | $43.07 | |
| EPS (diluted) | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | |
| Shares (basic, weighted) | 116M | 116M | 115M | 109M | 108M | 106M | 107M | 107M | 108M | 105M | |
| Shares (diluted, weighted) | 116M | 116M | 115M | 115M | 115M | 112M | 114M | 114M | 115M | 109M | |
| Depreciation & amortization | $105M | $145M | $148M | $210M | $236M | $286M | $341M | $421M | $483M | $544M | |
| EBITDA | $1.44B | $2.25B | $2.73B | $2.67B | $4.1B | $9.67B | $5.26B | $4.69B | $5.32B | $5.82B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-01